Salarius Pharmaceuticals Q2 2024 Earnings Report

Salarius Pharmaceuticals EPS Results

• Actual EPS: -$35.55
• Consensus EPS: -$804.00
• Beat/Miss: Beat by +$768.45
• One Year Ago EPS: N/A

Salarius Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Salarius Pharmaceuticals Announcement Details

• Quarter: Q2 2024
• Date: 8/9/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Salarius Pharmaceuticals (NASDAQ:SLRX) is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults. Seclidemstat is currently being evaluated in Phase 2 clinical studies, where the company is investigating its efficacy and safety profile in patients with relapsed or refractory disease.

In addition to its lead program, Salarius maintains a robust preclinical pipeline of small‐molecule candidates targeting fusion‐driven cancers and other oncology indications. These programs leverage proprietary chemistry platforms to identify novel inhibitors of NEDD8‐activating enzymes and other epigenetic regulators. By addressing oncogenic fusion proteins and key regulatory enzymes that drive tumor growth, Salarius aims to expand its portfolio of precision therapies for patients with unmet medical needs.

Founded in 2014 and headquartered in Houston, Texas, Salarius Pharmaceuticals has assembled a management team with extensive experience in oncology drug development, regulatory strategy, and commercialization. The company’s clinical trials are conducted primarily in the United States, with plans to extend development activities into Europe and other regions as part of its global strategy. Salarius also collaborates with academic institutions, patient advocacy groups and research consortia to advance its programs and accelerate the delivery of new cancer therapies to the clinic.